BOSTON, Mass. (August 23, 2019)— HotSpot Therapeutics, Inc, a biotechnology company pioneering the discovery of nature’s regulatory sites to advance […]
CAMBRIDGE, Mass. (October 30th, 2018) – HotSpot Therapeutics, a biotechnology company pioneering the discovery of nature’s regulatory sites to advance […]
“HotSpot is targeting natural regulatory sites on proteins that evolution has perfected over many millions of years. This allows us […]
Verge Scientific Communications 202.930.4762
DNA-encoded libraries are quickly surpassing traditional high throughput screens as industry’s first stop for hit generation. Now, developers are taking the technology up a notch to get more tractable hits in the output.
HotSpot Therapeutics, a biotech firm that launched last year to develop allosteric inhibitors for autoimmune and metabolic diseases, has acquired Macroceutics, a 5-year-old provider of DNA-encoded library screening technologies.
HotSpot is adding a key piece to its allosteric inhibitor platform through the acquisition of DNA-encoded library company Macroceutics: the technology to make chemical libraries tailored to allosteric, rather than active, sites.
Allosteric pockets on proteins have long been viewed as promising alternatives to active sites for controlling protein function. The problem has been finding them.
After decades of focus on proteins’ active sites, a new crop of biotech firms is shifting attention to proteins’ hidden regulatory pockets
HotSpot Therapeutics Inc. (Cambridge, Mass.) emerged from stealth on Tuesday with a $45 million series A round co-led by Atlas Venture and Sofinnova Partners. T
HotSpot Therapeutics is debuting with $45 million from Atlas Venture and Sofinnova Partners to explore allosteric inhibitors against tough-to-drug targets.
In real estate, location is key. The same holds true in the hunt for new drugs. HotSpot Therapeutics is trying to break new ground in drug discovery by hitting locations on a protein that aren’t the conventional targets of most medicines.
Atlas Venture and Sofinnova Partners co-lead investment in a couple of Nimbus alumni
HotSpot is pioneering a new approach to drugging the allosteric sites that Nature itself uses to control proteins.
In the quest towards building high-performing teams, biopharma can lift a page from the tech playbook around agile organizations.
With the discovery of the first allosteric inhibitors for bcr-abl that could offer the first clinical cures for CML, allosteric drug discovery is undergoing a resurgence.
